Advanced Kidney Failure and Hyperuricemia

Advances in Chronic Kidney Disease

Volumn 19, Issue 6, 2012, Pages 419-424

  Murea, Mariana ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic kidney disease; Gout; Hyperuricemia

Indexed keywords

ALLOPURINOL; ASCORBIC ACID; FEBUXOSTAT; PLACEBO; REACTIVE OXYGEN METABOLITE; URIC ACID;

CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLEARANCE; DISEASE ASSOCIATION; DISEASE COURSE; GOUT; HUMAN; HYPERURICEMIA; INCIDENCE; KIDNEY FAILURE; KINETICS; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PURINE METABOLISM; REVIEW;

GOUT; HUMANS; HYPERURICEMIA; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS; URIC ACID;

EID: 84867869977     PISSN: 15485595     EISSN: 15485609     Source Type: Journal    
DOI: 10.1053/j.ackd.2012.07.008     Document Type: Review

References (67)

1. Wu X.W., Muzny D.M., Lee C.C., Caskey C.T. Two independent mutational events in the loss of urate oxidase during hominoid evolution. J Mol Evol 1992, 34:78-84.
2. Becker B.F. Towards the physiological function of uric acid. Free Radic Biol Med 1993, 14:615-631.
3. Richette P., Bardin T. Gout. Lancet 2010, 375:318-328.
4. Chonchol M., Shlipak M.G., Katz R., et al. Relationship of uric acid with progression of kidney disease. Am J Kidney Dis 2007, 50:239-247.
5. Madero M., Sarnak M.J., Wang X., et al. Uric acid and long-term outcomes in CKD. Am J Kidney Dis 2009, 53:796-803.
6. Silverstein D.M., Srivaths P.R., Mattison P., et al. Serum uric acid is associated with high blood pressure in pediatric hemodialysis patients. Pediatr Nephrol 2011, 26:1123-1128.
7. Ohno I., Yamaguchi Y., Saikawa H., et al. Sevelamer decreases serum uric acid concentration through adsorption of uric acid in maintenance hemodialysis patients. Intern Med 2009, 48:415-420.
8. Neri L., Rocca Rey L.A., Lentine K.L., et al. Joint association of hyperuricemia and reduced GFR on cardiovascular morbidity: a historical cohort study based on laboratory and claims data from a national insurance provider. Am J Kidney Dis 2011, 58:398-408.
9. Kand'ar R., Zakova P., Muzakova V. Monitoring of antioxidant properties of uric acid in humans for a consideration measuring of levels of allantoin in plasma by liquid chromatography. Clin Chim Acta 2006, 365:249-256.
10. Causse E., Pradelles A., Dirat B., Negre-Salvayre A., Salvayre R., Couderc F. Simultaneous determination of allantoin, hypoxanthine, xanthine, and uric acid in serum/plasma by CE. Electrophoresis 2007, 28:381-387.
11. Shahbazian H., Zand M.A., Ehsanpour A., Khazaali M. Changes in plasma concentrations of hypoxanthine and uric acid before and after hemodialysis. Iran J Kidney Dis 2009, 3:151-155.
12. Suliman M.E., Johnson R.J., Garcia-Lopez E., et al. J-shaped mortality relationship for uric acid in CKD. Am J Kidney Dis 2006, 48:761-771.
13. Wen C.P., Cheng T.Y., Chan H.T., et al. Is high serum uric acid a risk marker or a target for treatment? Examination of its independent effect in a large cohort with low cardiovascular risk. Am J Kidney Dis 2010, 56:273-288.
14. Zheng S., de Las F.L., Bierhals A., et al. Relation of serum fetuin-A levels to coronary artery calcium in African-American patients on chronic hemodialysis. Am J Cardiol 2009, 103:46-49.
15. Hsu S.P., Pai M.F., Peng Y.S., Chiang C.K., Ho T.I., Hung K.Y. Serum uric acid levels show a 'J-shaped' association with all-cause mortality in haemodialysis patients. Nephrol Dial Transplant 2004, 19:457-462.
16. Latif W., Karaboyas A., Tong L., et al. Uric acid levels and all-cause and cardiovascular mortality in the hemodialysis population. Clin J Am Soc Nephrol 2011, 6:2470-2477.
17. Chen Y., Ding X., Teng J., et al. Serum uric acid is inversely related to acute ischemic stroke morbidity in hemodialysis patients. Am J Nephrol 2011, 33:97-104.
18. Rosolowsky E.T., Ficociello L.H., Maselli N.J., et al. High-normal serum uric acid is associated with impaired glomerular filtration rate in nonproteinuric patients with type 1 diabetes. Clin J Am Soc Nephrol 2008, 3:706-713.
19. Rieselbach R.E., Steele T.H. Intrinsic renal disease leading to abnormal urate excretion. Nephron 1975, 14:81-87.
20. Vaziri N.D., Freel R.W., Hatch M. Effect of chronic experimental renal insufficiency on urate metabolism. J Am Soc Nephrol 1995, 6:1313-1317.
21. Hatch M., Vaziri N.D. Enhanced enteric excretion of urate in rats with chronic renal failure. Clin Sci (Lond) 1994, 86:511-516.
22. Hediger M.A., Johnson R.J., Miyazaki H., Endou H. Molecular physiology of urate transport. Physiology (Bethesda) 2005, 20:125-133.
23. Chai J., Luo D., Wu X., et al. Changes of organic anion transporter MRP4 and related nuclear receptors in human obstructive cholestasis. J Gastrointest Surg 2011, 15:996-1004.
24. Feig D.I., Kang D.H., Johnson R.J. Uric acid and cardiovascular risk. N Engl J Med 2008, 23(359):1811-1821.
25. Dounousi E., Papavasiliou E., Makedou A., et al. Oxidative stress is progressively enhanced with advancing stages of CKD. Am J Kidney Dis 2006, 48:752-760.
26. Filiopoulos V., Hadjiyannakos D., Takouli L., Metaxaki P., Sideris V., Vlassopoulos D. Inflammation and oxidative stress in end-stage renal disease patients treated with hemodialysis or peritoneal dialysis. Int J Artif Organs 2009, 32:872-882.
27. Valko M., Leibfritz D., Moncol J., Cronin M.T., Mazur M., Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007, 39:44-84.
28. Bogeski I., Kappl R., Kummerow C., Gulaboski R., Hoth M., Niemeyer B.A. Redox regulation of calcium ion channels: chemical and physiological aspects. Cell Calcium 2011, 50:407-423.
29. Kaur H., Halliwell B. Action of biologically-relevant oxidizing species upon uric acid. Identification of uric acid oxidation products. Chem Biol Interact 1990, 73:235-247.
30. Clermont G., Lecour S., Lahet J., et al. Alteration in plasma antioxidant capacities in chronic renal failure and hemodialysis patients: a possible explanation for the increased cardiovascular risk in these patients. Cardiovasc Res 2000, 47:618-623.
31. Locatelli F., Canaud B., Eckardt K.U., Stenvinkel P., Wanner C., Zoccali C. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant 2003, 18:1272-1280.
32. Clermont G., Lecour S., Cabanne J.F., et al. Vitamin E-coated dialyzer reduces oxidative stress in hemodialysis patients. Free Radic Biol Med 2001, 31:233-241.
33. Mydlik M., Derzsiova K., Racz O., et al. Vitamin E-coated dialyzer and antioxidant defense parameters: three-month study. Semin Nephrol 2004, 24:525-531.
34. Yang C.C., Hsu S.P., Wu M.S., Hsu S.M., Chien C.T. Effects of vitamin C infusion and vitamin E-coated membrane on hemodialysis-induced oxidative stress. Kidney Int 2006, 69:706-714.
35. Ames B.N., Cathcart R., Schwiers E., Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A 1981, 78:6858-6862.
36. Grootveld M., Halliwell B. Measurement of allantoin and uric acid in human body fluids. A potential index of free-radical reactions in vivo?. Biochem J 1987, 243:803-808.
37. Hall Y.N., Sugihara J.G., Go A.S., Chertow G.M. Differential mortality and transplantation rates among Asians and Pacific Islanders with ESRD. J Am Soc Nephrol 2005, 16:3711-3720.
38. Lee Y.S., Yang J.H., Choi J.C., Eun H.C. Age-dependent change of uric acid level in the dermis using cutaneous microdialysis. Gerontology 2005, 51:231-233.
39. Portugal-Cohen M., Oron M., Ma'or Z., et al. Noninvasive skin measurements to monitor chronic renal failure pathogenesis. Biomed Pharmacother 2011, 65:280-285.
40. Simoyi M.F., Van D.K., Klandorf H. Manipulation of plasma uric acid in broiler chicks and its effect on leukocyte oxidative activity. Am J Physiol Regul Integr Comp Physiol 2002, 282:R791-R796.
41. McFarland D.C., Kenzy S.G., Coon C.N. A micromethod for plasma uric acid determinations in companion birds. Avian Dis 1979, 23:772-774.
42. Cutler R.G. Urate and ascorbate: their possible roles as antioxidants in determining longevity of mammalian species. Arch Gerontol Geriatr 1984, 3:321-348.
43. Vanholder R.C., De Smet R.V., Ringoir S.M. Assessment of urea and other uremic markers for quantification of dialysis efficacy. Clin Chem 1992, 38(8 Pt 1):1429-1436.
44. Causse E., Ribes D., Longlune N., et al. Aminothiols and allantoin in chronic dialysis patients: effects of hemodialysis sessions. Clin Nephrol 2010, 73:51-57.
45. Meert N., Eloot S., Waterloos M.A., et al. Effective removal of protein-bound uraemic solutes by different convective strategies: a prospective trial. Nephrol Dial Transplant 2009, 24:562-570.
46. Chen T.S., Liou S.Y., Chang Y.L. The clearance of unidentified uremic solutes (with molecular weight under 5 kDa) plays an important role in hemodialyzer selection. Int Urol Nephrol 2010, 42:465-470.
47. Choi J.Y., Yoon Y.J., Choi H.J., et al. Dialysis modality-dependent changes in serum metabolites: accumulation of inosine and hypoxanthine in patients on haemodialysis. Nephrol Dial Transplant 2011, 26:1304-1313.
48. Fagugli R.M., De Smet R., Buoncristiani U., Lameire N., Vanholder R. Behavior of non-protein-bound and protein-bound uremic solutes during daily hemodialysis. Am J Kidney Dis 2002, 40:339-347.
49. Sasaki K., Motomiya Y., Oyama N., et al. Plasma allantoin in patients undergoing maintenance hemodialysis. Nihon Jinzo Gakkai Shi 1996, 38:164-170. [In Japanese].
50. Liu W.C., Hung C.C., Chen S.C., et al. Association of hyperuricemia with renal outcomes, cardiovascular disease, and mortality. Clin J Am Soc Nephrol 2012, 7:541-548.
51. Navaneethan S.D., Beddhu S. Associations of serum uric acid with cardiovascular events and mortality in moderate chronic kidney disease. Nephrol Dial Transplant 2009, 24:1260-1266.
52. Lee S.M., Lee A.L., Winters T.J., et al. Low serum uric acid level is a risk factor for death in incident hemodialysis patients. Am J Nephrol 2009, 29:79-85.
53. Mutluay R., Konca C., Erten Y., et al. Predictive markers of asymptomatic atherosclerosis in end-stage renal disease patients. Ren Fail 2010, 32:448-454.
54. Tangri N., Weiner D.E. Uric acid, CKD, and cardiovascular disease: confounders, culprits, and circles. Am J Kidney Dis 2010, 56:247-250.
55. Ohno I., Ichida K., Okabe H., et al. Frequency of gouty arthritis in patients with end-stage renal disease in Japan. Intern Med 2005, 44:706-709.
56. Ifudu O., Tan C.C., Dulin A.L., Delano B.G., Friedman E.A. Gouty arthritis in end-stage renal disease: clinical course and rarity of new cases. Am J Kidney Dis 1994, 23:347-351.
57. Cohen S.D., Kimmel P.L., Neff R., Agodoa L., Abbott K.C. Association of incident gout and mortality in dialysis patients. J Am Soc Nephrol 2008, 19:2204-2210.
58. Chonchol M. Neutrophil dysfunction and infection risk in end-stage renal disease. Semin Dial 2006, 19:291-296.
59. Choi H.M., Woo Y.S., Kim M.G., Jo S.K., Cho W.Y., Kim H.K. Altered monocyte-derived dendritic cell function in patients on hemodialysis: a culprit for underlying impaired immune responses. Clin Exp Nephrol 2011, 15:546-553.
60. Schreiner O., Wandel E., Himmelsbach F., Galle P.R., Marker-Hermann E. Reduced secretion of proinflammatory cytokines of monosodium urate crystal-stimulated monocytes in chronic renal failure: an explanation for infrequent gout episodes in chronic renal failure patients?. Nephrol Dial Transplant 2000, 15:644-699.
61. Laakso J.T., Teravainen T.L., Martelin E., Vaskonen T., Lapatto R. Renal xanthine oxidoreductase activity during development of hypertension in spontaneously hypertensive rats. J Hypertens 2004, 22:1333-1340.
62. Xu X., Hu X., Lu Z., et al. Xanthine oxidase inhibition with febuxostat attenuates systolic overload-induced left ventricular hypertrophy and dysfunction in mice. J Card Fail 2008, 14:746-753.
63. Paoletti E., Bellino D., Cassottana P., Rolla D., Cannella G. Left ventricular hypertrophy in nondiabetic predialysis CKD. Am J Kidney Dis 2005, 46:320-327.
64. Zoccali C., Benedetto F.A., Mallamaci F., et al. Left ventricular mass monitoring in the follow-up of dialysis patients: prognostic value of left ventricular hypertrophy progression. Kidney Int 2004, 65:1492-1498.
65. Kao M.P., Ang D.S., Gandy S.J., et al. Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease. J Am Soc Nephrol 2011, 22:1382-1389.
66. Nakaya I., Namikoshi T., Tsuruta Y., et al. Management of asymptomatic hyperuricaemia in patients with chronic kidney disease by Japanese nephrologists: a questionnaire survey. Nephrology (Carlton) 2011, 16:518-521.
67. Becker M.A., Schumacher H.R., Wortmann R.L., et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005, 353:2450-2461.